Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


So Far So Good: With Phase III Data, Keryx Says Zerenex Will Stand Out In ESRD Crowd

This article was originally published in The Pink Sheet Daily

Executive Summary

Company set to price drug up to 20% below Genzyme's market leading Renvela/Renagel franchise, and ponders impact of new Medicare bundling regime for phosphate binders used in end-stage renal disease.

You may also be interested in...

Keryx Aims For Ironclad Hold On Hyperphosphatemia Market

Recently-approved (and still un-trade named) phosphate binder ferric citrate could unseat the market leader due to its unique ability to increase iron in patients, firm believes, although it didn’t get the full set of labeling claims it sought.

Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting

Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.

As Keryx Moves Closer To Phase III Results, Partnership Options Heat Up

Phase III data readout on perifosine in colorectal cancer patients will spark a partnership or acquisition, CEO Ron Bentsur predicts during a Q2 call.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts